Merck Forecasts 2024 Sales Of $62.7B-$64.2B, With Adjusted EPS Of $8.44-$8.59 Compared To Consensus Of $63.31B And $8.42, Respectively
Portfolio Pulse from Benzinga Newsdesk
Merck has projected its 2024 sales to be between $62.7 billion and $64.2 billion, with an adjusted EPS of $8.44 to $8.59, slightly above the consensus estimates of $63.31 billion in sales and an EPS of $8.42.
February 01, 2024 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's 2024 sales and EPS projections exceed consensus estimates, indicating a positive outlook for the company's financial performance.
Merck's forecast surpassing consensus estimates suggests investor confidence and a potentially stronger market position, likely leading to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100